DAPTOMYCIN injection, powder, lyophilized, for solution

Country: Amerika Syarikat

Bahasa: Inggeris

Sumber: NLM (National Library of Medicine)

Bahan aktif:

DAPTOMYCIN (UNII: NWQ5N31VKK) (DAPTOMYCIN - UNII:NWQ5N31VKK)

Boleh didapati daripada:

BluePoint Laboratories

Laluan pentadbiran:

INTRAVENOUS

Jenis preskripsi:

PRESCRIPTION DRUG

Tanda-tanda terapeutik:

Daptomycin for injection is indicated for the treatment of adult and pediatric patients (1 to 17 years of age) with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria:  Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis , and  Enterococcus faecalis  (vancomycin-susceptible isolates only). Daptomycin for injection is indicated for the treatment of adult patients with Staphylococcus aureus bloodstream infections (bacteremia), including adult patients with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates.   Daptomycin for injection is indicated for the treatment of pediatric patients (1 to 17 years of age) with

Ringkasan produk:

Daptomycin for injection is supplied as a sterile pale yellow to light brown lyophilized cake or powder in a single-dose vial containing 500 mg of daptomycin: Package of 1 (NDC 68001-376-68). Store original packages at refrigerated temperatures, 2°C to 8°C (36°F to 46°F); avoid excessive heat. Storage conditions for the reconstituted and diluted solutions are described in another section of the prescribing information [see Dosage and Administration ( 2.7)].

Status kebenaran:

Abbreviated New Drug Application

Ciri produk

DAPTOMYCIN- DAPTOMYCIN INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
BLUEPOINT LABORATORIES
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
DAPTOMYCIN FOR
INJECTION SAFELY AND EFFECTIVELY.
SEE FULL PRESCRIBING INFORMATION FOR DAPTOMYCIN FOR INJECTION.
DAPTOMYCIN FOR INJECTION, FOR INTRAVENOUS USE
INITIAL U.S. APPROVAL: 2003
RECENT MAJOR CHANGES
Dosage and Administration(2) 2/2022
Warnings and Precautions, Development of Drug-Resistant Bacteria (
5.12) 10/2021
INDICATIONS AND USAGE
Daptomycin for injection is a lipopeptide antibacterial indicated for
the treatment of:
1. Complicated skin and skin structure infections (cSSSI) in adult and
pediatric patients (1 to 17 years of
age) ( 1.1) and,
2. _ Staphylococcus aureus_ bloodstream infections (bacteremia), in
adult patients including those with
right-sided infective endocarditis ( 1.2)
3. _ Staphylococcus aureus_ bloodstream infections (bacteremia) in
pediatric patients (1 to 17 years of age).
( 1.3)
Limitations of Use:
1. Daptomycin for injection is not indicated for the treatment of
pneumonia. ( 1.4)
2. Daptomycin for injection is not indicated for the treatment of
left-sided infective endocarditis due to _S._
_aureus_. ( 1.4)
3. Daptomycin for injection is not recommended in pediatric patients
younger than one year of age due to
the risk of potential effects on muscular, neuromuscular, and/or
nervous systems (either peripheral
and/or central) observed in neonatal dogs. ( 1.4)
To reduce the development of drug-resistant bacteria and maintain the
effectiveness of daptomycin for
injection and other antibacterial drugs, daptomycin for injection
should be used to treat or prevent
infections that are proven or strongly suspected to be caused by
bacteria. ( 1.5)
DOSAGE AND ADMINISTRATION
Adult Patients
1. Administer to ADULT PATIENTS intravenously in 0.9% sodium chloride,
either by injection over a 2-
minute period or by infusion over a 30-minute period. ( 2.1, 2.7)
2. Recommended dosage regimen for adult